Firefly Neuroscience's Loss Widens to $14.76M Despite Revenue Jump

TL;DR

**AIFF is burning cash and relying on dilutive financing, making it a high-risk bet despite revenue growth and a strategic acquisition.**

AI Summary

FIREFLY NEUROSCIENCE, INC. (AIFF) reported a significant increase in net loss and revenue for the six months ended June 30, 2025. The company's net loss widened dramatically to $14.76 million, up from $2.39 million in the prior year, primarily due to a $9.37 million change in derivative fair value and a $1.35 million loss on settlement. Revenue, however, saw substantial growth, reaching $342,000 for the six months ended June 30, 2025, compared to $22,000 in the same period of 2024. Operating expenses more than doubled to $4.02 million from $2.37 million, driven by a surge in general and administration expenses to $2.96 million. The company acquired Evoke Neuroscience, Inc. on April 30, 2025, for $3.00 million in cash and $2.74 million in shares, contributing to a substantial increase in goodwill to $5.18 million and intangible assets to $1.10 million. Cash increased to $5.92 million from $1.81 million at December 31, 2024, largely due to $11.39 million in financing activities, including $8.83 million from warrant exercises. Despite increased cash, the company faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative operating cash flow of $4.90 million.

Why It Matters

This filing reveals Firefly Neuroscience's aggressive expansion through the Evoke Neuroscience acquisition, which significantly boosted its asset base but also contributed to a massive net loss. For investors, the substantial doubt about going concern, coupled with recurring losses and reliance on capital raises, signals high risk. Employees might face uncertainty given the company's financial instability, despite growth in operations. Customers could benefit from an expanded product offering through the Evoke acquisition, but the company's long-term viability remains a question. In the competitive neuroscience technology market, AIFF's ability to integrate Evoke and achieve profitability will be critical for its survival and market position.

Risk Assessment

Risk Level: high — The company explicitly states "These conditions raise substantial doubt about the Company's ability to continue as a going concern" due to an accumulated deficit of $106.26 million and negative cash flow from operating activities of $4.90 million for the six months ended June 30, 2025. Furthermore, the net loss dramatically increased to $14.76 million, indicating significant financial challenges.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the explicit going concern warning and substantial losses, a 'wait and see' approach is prudent, monitoring for sustained profitability and reduced reliance on external financing before considering a position.

Financial Highlights

debt To Equity

0.23

revenue

$342K

operating Margin

-1081%

total Assets

$14.94M

total Debt

$2.84M

net Income

-$14.76M

eps

N/A

gross Margin

93%

cash Position

$5.92M

revenue Growth

+1455%

Revenue Breakdown

Key Numbers

• $14.76M — Net Loss (Increased from $2.39M in prior year, primarily due to derivative fair value changes.)
• $342K — Revenue (Increased significantly from $22K in prior year, indicating business growth.)
• $4.02M — Total Operating Expenses (More than doubled from $2.37M, driven by general and administration costs.)
• $5.92M — Cash (Increased from $1.81M, largely due to financing activities.)
• $4.90M — Net Cash Used in Operating Activities (Negative cash flow, highlighting ongoing operational burn.)
• $106.26M — Accumulated Deficit (Indicates significant historical losses and raises going concern doubts.)
• $5.18M — Goodwill (Resulted from the acquisition of Evoke Neuroscience, Inc.)
• 13,298,838 — Common Shares Outstanding (Increased from 8,122,060, indicating significant dilution.)
• $8.83M — Proceeds from Warrant Exercises (Key source of cash for the period.)
• $2.74M — Shares Issued for Evoke Acquisition (Part of the consideration for the Evoke Neuroscience acquisition.)

Key Players & Entities

• FIREFLY NEUROSCIENCE, INC. (company) — registrant
• Evoke Neuroscience, Inc. (company) — acquired company
• Nasdaq Capital Market (regulator) — exchange where AIFF is registered
• $14.76 million (dollar_amount) — net loss for six months ended June 30, 2025
• $342,000 (dollar_amount) — revenue for six months ended June 30, 2025
• $9.37 million (dollar_amount) — change in derivative fair value
• $1.35 million (dollar_amount) — loss on settlement
• $5.92 million (dollar_amount) — cash balance as of June 30, 2025
• $4.90 million (dollar_amount) — net cash used in operating activities for six months ended June 30, 2025
• $106.26 million (dollar_amount) — accumulated deficit as of June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has recurring losses and a negative operating cash flow of $4.90 million for the six months ended June 30, 2025. This, coupled with an accumulated deficit of $106.26 million, raises substantial doubt about its ability to continue as a going concern.
• Derivative Fair Value Volatility [medium — financial]: A significant $9.37 million change in derivative fair value negatively impacted the net loss for the six months ended June 30, 2025. This volatility introduces unpredictability into the company's financial results.
• Increased Operating Expenses [medium — operational]: Total operating expenses more than doubled to $4.02 million from $2.37 million for the six months ended June 30, 2025. This surge was primarily driven by a substantial increase in general and administration expenses to $2.96 million.
• Dilution from Share Issuances [medium — financial]: Common shares outstanding increased from 8,122,060 to 13,298,838, a significant rise indicating substantial dilution for existing shareholders. This was partly due to shares issued for the Evoke acquisition ($2.74 million).
• Acquisition Integration Risks [medium — financial]: The acquisition of Evoke Neuroscience, Inc. for $3.00 million cash and $2.74 million in shares resulted in $5.18 million in goodwill and $1.10 million in intangible assets. Integration challenges and the realization of expected synergies pose operational and financial risks.
• Loss on Settlement [low — financial]: The company incurred a $1.35 million loss on settlement during the six months ended June 30, 2025. The nature and implications of this settlement require further scrutiny.

Industry Context

The neuroscience sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing and strategic acquisitions to advance their technologies. The competitive landscape includes established pharmaceutical giants and numerous biotech startups vying for breakthroughs in areas like neurodegenerative diseases and neurological disorders.

Regulatory Implications

As a neuroscience company, AIFF is subject to stringent regulatory oversight from bodies like the FDA. Clinical trial failures, delays in regulatory approvals, and evolving compliance standards pose significant risks. The company must navigate complex regulations related to drug development, manufacturing, and marketing.

What Investors Should Do

1. Monitor cash burn and runway closely.
2. Evaluate the integration and performance of Evoke Neuroscience, Inc.
3. Analyze the impact of derivative fair value changes.
4. Assess the sustainability of revenue growth.

Key Dates

• 2025-04-30: Acquisition of Evoke Neuroscience, Inc. — Significantly increased goodwill and intangible assets, and contributed to higher operating expenses and potential future revenue streams.
• 2025-06-30: End of Six-Month Reporting Period — Period marked by substantial revenue growth, a dramatic increase in net loss, significant financing activities, and a going concern warning.

Glossary

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. It represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and recognized. (The $5.18 million in goodwill resulted from the acquisition of Evoke Neuroscience, Inc., indicating a premium paid over the net identifiable assets acquired.)

Intangible Assets, net

Non-physical assets that have value, such as patents, copyrights, trademarks, and customer lists. 'Net' indicates that accumulated amortization has been deducted. (The $1.10 million in net intangible assets from the Evoke acquisition suggests the presence of valuable intellectual property or other non-physical assets.)

Derivative Liability

A liability arising from a financial derivative contract whose value is derived from an underlying asset, index, or rate. Changes in the fair value of these liabilities can significantly impact earnings. (The company had a derivative liability of $827K at December 31, 2024, and a $9.37 million change in its fair value contributed significantly to the net loss in the current period.)

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total historical losses incurred since the company's inception. (The $106.26 million accumulated deficit highlights the company's long history of unprofitability and is a key factor in the going concern assessment.)

Warrant Exercises

The act of a holder of a warrant (a security giving the holder the option to purchase stock at a specific price) exercising that option, thereby providing capital to the company. (Proceeds of $8.83 million from warrant exercises were a major source of cash, helping to increase the company's cash position.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The company's recurring losses and negative cash flow have led to substantial doubt about its ability to continue as a going concern.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Firefly Neuroscience has experienced a dramatic increase in its net loss, widening from $2.39 million to $14.76 million, largely due to a significant $9.37 million change in derivative fair value and a $1.35 million loss on settlement. Revenue has seen a substantial surge, growing from $22,000 to $342,000, indicating promising top-line growth. However, operating expenses have more than doubled from $2.37 million to $4.02 million, driven by increased general and administration costs. The company also completed a significant acquisition, adding goodwill and intangible assets, while financing activities, particularly warrant exercises, bolstered cash reserves.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share AIFF Nasdaq Capital Marke

Filing Documents

• wavd20250630c_10q.htm (10-Q) — 1407KB
• ex_831966.htm (EX-31.1) — 9KB
• ex_831967.htm (EX-31.2) — 9KB
• ex_831968.htm (EX-32.1) — 5KB
• ex_832565.htm (EX-32.2) — 5KB
• 0001437749-25-026538.txt ( ) — 7270KB
• aiff-20250630.xsd (EX-101.SCH) — 67KB
• aiff-20250630_cal.xml (EX-101.CAL) — 52KB
• aiff-20250630_def.xml (EX-101.DEF) — 439KB
• aiff-20250630_lab.xml (EX-101.LAB) — 402KB
• aiff-20250630_pre.xml (EX-101.PRE) — 486KB
• wavd20250630c_10q_htm.xml (XML) — 1142KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Page Number Item 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Equity (Deficit) for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 6 Notes to Condensed Consolidated Financial Statements (Unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 28

Signatures

Signatures 29 2 Table of Contents Part I. Financial Information

Financial Statements

Item 1. Financial Statements. FIREFLY NEUROSCIENCE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS AS OF June 30, 2025 AND DECEMBER 31, 2024 (IN THOUSANDS, EXCEPT SHARE DATA) June 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets Cash $ 5,918 $ 1,810 Other receivables 197 121 Prepaid expenses 1,283 697 Inventory 133 - Total current assets 7,531 2,628 Non current assets Prepaid expenses 1,000 1,657 Equipment, net 135 136 Intangible assets, net 1,097 180 Goodwill 5,175 - Total non current assets 7,407 1,973 TOTAL ASSETS $ 14,938 $ 4,601 LIABILITIES Current liabilities Trade payables $ 1,502 $ 1,816 Accrued liabilities 532 1,626 Deferred revenue 283 13 Convertible promissory note, net of unamortized discount - 694 Deemed dividend liability - - Contingent consideration payable 478 - Derivative liability - 827 Total current liabilities 2,795 4,976 Non current liabilities Deferred revenue 43 - TOTAL LIABILITIES $ 2,838 $ 4,976 COMMITMENTS AND CONTINGENCIES (Note 12) SHAREHOLDERS ' EQUITY (DEFICIT) Preferred shares, $ 0.0001 par value: 1,000,000 shares authorized; nil issued and outstanding at June 30, 2025 and December 31, 2024 - - Common shares, $ 0.0001 par value: 100,000,000 shares authorized; 13,298,838 and 8,122,060 issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1 - Additional paid-in capital 118,356 86,709 Accumulated deficit ( 106,257 ) ( 87,084 ) TOTAL SHAREHOLDERS ' EQUITY (DEFICIT) 12,100 ( 375 ) TOTAL LIABILITIES AND SHAREHOLDERS ' EQUITY $ 14,938 $ 4,601 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents FIREFLY NEUROSCIENCE, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024 (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Three Mon

View Full Filing

View this 10-Q filing on SEC EDGAR